El-Atawneh S, Goldblum A
Int J Mol Sci. 2024; 25(18).
PMID: 39337714
PMC: 11432050.
DOI: 10.3390/ijms251810230.
Zheng Y, Gao M, Wijtmans M, Vischer H, Leurs R
Pharmaceuticals (Basel). 2024; 17(4).
PMID: 38675496
PMC: 11053687.
DOI: 10.3390/ph17040536.
Peng X, Yang L, Liu Z, Lou S, Mei S, Li M
Nat Commun. 2022; 13(1):6105.
PMID: 36243875
PMC: 9569329.
DOI: 10.1038/s41467-022-33880-y.
Mika K, Szafarz M, Zadrozna M, Nowak B, Bednarski M, Szczepanska K
Int J Mol Sci. 2022; 23(13).
PMID: 35806019
PMC: 9266460.
DOI: 10.3390/ijms23137011.
Wang Y, Huang X, Fan H, An H, Ma T, Zhang Q
Front Psychiatry. 2021; 12:762656.
PMID: 34790138
PMC: 8591287.
DOI: 10.3389/fpsyt.2021.762656.
Cytosolic Phospholipase A2 Is Required for Fexofenadine's Therapeutic Effects against Inflammatory Bowel Disease in Mice.
Zhao X, Liu R, Chen Y, Hettinghouse A, Liu C
Int J Mol Sci. 2021; 22(20).
PMID: 34681815
PMC: 8539349.
DOI: 10.3390/ijms222011155.
Fexofenadine Protects Against Intervertebral Disc Degeneration Through TNF Signaling.
Liu K, Wei J, Li G, Liu R, Zhao D, Zhang Y
Front Cell Dev Biol. 2021; 9:687024.
PMID: 34504840
PMC: 8421647.
DOI: 10.3389/fcell.2021.687024.
Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against inflammatory arthritis.
Liu R, Chen Y, Fu W, Wang S, Cui Y, Zhao X
Ann Rheum Dis. 2019; 78(11):1524-1535.
PMID: 31302596
PMC: 8157820.
DOI: 10.1136/annrheumdis-2019-215543.
Structure-Activity Relationship of Hetarylpropylguanidines Aiming at the Development of Selective Histamine Receptor Ligands.
Pockes S, Wifling D, Buschauer A, Elz S
ChemistryOpen. 2019; 8(3):285-297.
PMID: 30886786
PMC: 6401531.
DOI: 10.1002/open.201900011.
Synthesis and Characterization of a Bidirectional Photoswitchable Antagonist Toolbox for Real-Time GPCR Photopharmacology.
Hauwert N, Mocking T, da Costa Pereira D, Kooistra A, Wijnen L, Vreeker G
J Am Chem Soc. 2018; 140(12):4232-4243.
PMID: 29470065
PMC: 5879491.
DOI: 10.1021/jacs.7b11422.
Histamine and Skin Barrier: Are Histamine Antagonists Useful for the Prevention or Treatment of Atopic Dermatitis?.
Benedetto A, Yoshida T, Fridy S, Park J, Kuo I, Beck L
J Clin Med. 2015; 4(4):741-55.
PMID: 26239353
PMC: 4470164.
DOI: 10.3390/jcm4040741.
Sodium binding to hH3R and hH 4R--a molecular modeling study.
Wittmann H, Seifert R, Strasser A
J Mol Model. 2014; 20(8):2394.
PMID: 25098339
DOI: 10.1007/s00894-014-2394-2.
Procognitive properties of drugs with single and multitargeting H3 receptor antagonist activities.
Nikolic K, Filipic S, Agbaba D, Stark H
CNS Neurosci Ther. 2014; 20(7):613-23.
PMID: 24836924
PMC: 6493064.
DOI: 10.1111/cns.12279.
The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.
Alexander S, Benson H, Faccenda E, Pawson A, Sharman J, Spedding M
Br J Pharmacol. 2014; 170(8):1459-581.
PMID: 24517644
PMC: 3892287.
DOI: 10.1111/bph.12445.
Luciferase reporter gene assay on human, murine and rat histamine H4 receptor orthologs: correlations and discrepancies between distal and proximal readouts.
Nordemann U, Wifling D, Schnell D, Bernhardt G, Stark H, Seifert R
PLoS One. 2013; 8(9):e73961.
PMID: 24023919
PMC: 3759464.
DOI: 10.1371/journal.pone.0073961.
A structural chemogenomics analysis of aminergic GPCRs: lessons for histamine receptor ligand design.
Kooistra A, Kuhne S, de Esch I, Leurs R, de Graaf C
Br J Pharmacol. 2013; 170(1):101-26.
PMID: 23713847
PMC: 3764853.
DOI: 10.1111/bph.12248.
Preclinical evaluation of the abuse potential of Pitolisant, a histamine H₃ receptor inverse agonist/antagonist compared with Modafinil.
Uguen M, Perrin D, Belliard S, Ligneau X, Beardsley P, Lecomte J
Br J Pharmacol. 2013; 169(3):632-44.
PMID: 23472741
PMC: 3682710.
DOI: 10.1111/bph.12149.
Design and pharmacological characterization of VUF14480, a covalent partial agonist that interacts with cysteine 98(3.36) of the human histamine H₄ receptor.
Nijmeijer S, Engelhardt H, Schultes S, van de Stolpe A, Lusink V, de Graaf C
Br J Pharmacol. 2013; 170(1):89-100.
PMID: 23347159
PMC: 3764852.
DOI: 10.1111/bph.12113.
Molecular and cellular analysis of human histamine receptor subtypes.
Seifert R, Strasser A, Schneider E, Neumann D, Dove S, Buschauer A
Trends Pharmacol Sci. 2012; 34(1):33-58.
PMID: 23254267
PMC: 3869951.
DOI: 10.1016/j.tips.2012.11.001.
Histamine H3 receptor antagonists/inverse agonists on cognitive and motor processes: relevance to Alzheimer's disease, ADHD, schizophrenia, and drug abuse.
Vohora D, Bhowmik M
Front Syst Neurosci. 2012; 6:72.
PMID: 23109919
PMC: 3478588.
DOI: 10.3389/fnsys.2012.00072.